Yes, there are legitimate medical indications for this ivermectin dosing regimen
The regimen of ivermectin 12 mg daily for three consecutive days, repeated one week later, has legitimate use for specific parasitic infections, particularly strongyloidiasis in immunocompromised patients and body lice infestations, but is NOT indicated for COVID-19.
FDA-Approved Indications
The FDA approves ivermectin for two primary conditions 1:
- Strongyloidiasis (intestinal infection with Strongyloides stercoralis)
- Onchocerciasis (infection with Onchocerca volvulus)
The standard FDA-approved dosing is typically a single dose of 200 mcg/kg (approximately 12 mg for a 60 kg person) 1.
When Multi-Day or Repeated Dosing Is Legitimate
Strongyloidiasis in Immunocompromised Patients
This is the most compelling indication for repeated dosing. The FDA label explicitly states that immunocompromised patients (including HIV-infected individuals) may require repeated courses of therapy, with several treatments at 2-week intervals potentially necessary 1. Research confirms that double-dose ivermectin (two doses given two weeks apart) achieves 93.1% cure rates versus 96.8% for single dose in patients with concomitant illnesses 2.
Body Lice Infestation
A study demonstrated that three doses of oral ivermectin 12 mg each, administered at 7-day intervals, dramatically reduced body lice burden from 1,898 lice to 6 lice over 14 days, with prevalence dropping from 84.9% to 18.5% 3. This represents a legitimate off-label use for this specific dosing pattern.
Scabies Treatment
While not exactly matching your described regimen, evidence strongly supports that two doses one week apart is superior to single-dose treatment, with 98% clearance versus only 58% with single dose 4. The absence of a second dose is a major predictor of treatment failure.
Loiasis Considerations - Critical Safety Concern
If the patient has had exposure to West or Central Africa, pretreatment assessment for Loa loa infection is mandatory 1. Patients heavily infected with Loa loa can develop serious or fatal encephalopathy following ivermectin treatment, with symptoms including confusion, seizures, coma, and incontinence 1. Recent guidelines recommend ivermectin only below 8,000 microfilariae/mL for loiasis, with some allowing up to 30,000 mf/mL 5.
NOT Legitimate for COVID-19
Ivermectin should NOT be used for COVID-19 prevention or treatment. Meta-analysis of 40 RCTs with 23,243 participants found no statistically significant reduction in mortality for hospitalized patients (RR 0.94) or outpatients (RR 0.88), no reduction in infection rate (RR 0.37), and no difference in adverse events 6. A focused analysis of 12 RCTs with 7,035 non-hospitalized patients similarly showed no benefit for hospitalization (RR 0.81), mortality (RR 0.98), or clinical outcomes 7.
Safety Concerns with Repeated Dosing
Recent toxicology research raises concerns about repeated ivermectin administration. A study using 12 mg/kg daily for 5 days in rats (modeling repeated human dosing) demonstrated:
- Delayed neuropsychiatric effects appearing 14 days post-treatment
- Persistent depression-like behavior and hyperlocomotion
- Oxidative stress and enzyme disruption
- Potential hepatotoxicity 8
While animal models don't directly translate to humans, this suggests caution with frequent repeated dosing beyond established protocols.
Clinical Algorithm for This Regimen
Use this specific regimen (12 mg daily × 3 days, repeated in 1 week) for:
- Body lice infestation - well-supported by evidence 3
- Strongyloidiasis in immunocompromised patients who failed initial single-dose therapy 1, 2
Do NOT use for:
- COVID-19 (any indication) 6, 7
- Standard strongyloidiasis in immunocompetent patients (single or double dose sufficient) 2
Before prescribing, always:
- Screen for Loa loa exposure history (West/Central Africa travel)
- Assess liver function given hepatotoxicity risk
- Ensure patient takes medication on empty stomach with water 1
- Monitor for neuropsychiatric symptoms if repeated dosing required